NO944928L - Fremgangsmåter for inhibering av Alzheimers sykdom - Google Patents

Fremgangsmåter for inhibering av Alzheimers sykdom

Info

Publication number
NO944928L
NO944928L NO944928A NO944928A NO944928L NO 944928 L NO944928 L NO 944928L NO 944928 A NO944928 A NO 944928A NO 944928 A NO944928 A NO 944928A NO 944928 L NO944928 L NO 944928L
Authority
NO
Norway
Prior art keywords
methods
disease
human
compound
formula
Prior art date
Application number
NO944928A
Other languages
English (en)
Other versions
NO944928D0 (no
Inventor
Patrick Cornelious May
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO944928D0 publication Critical patent/NO944928D0/no
Publication of NO944928L publication Critical patent/NO944928L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Det er beskrevet fremgangsmåter for Inhibering av Alzheimers sykdom Innbefattende administrering til et menneske som har behov for dette, av en effektiv mengde av en forbindelse av formel I OCH2CHi¿R2 (D hvor R1 og R3 uavhengig av hverandre betyr hydrogen, O O II II ' -CH3, -C-fCj-Cfc alkyl), eller -C-Ar, hvor Ar er eventuelt substituert fenyl; R2 er valgt fra gruppen bestående av pyrrolldin, heksametylenimino og piperidino; eller et farmasøytisk akseptabelt salt eller solvat derav. Det er videre beskrevet fremgangsmåter for å øke TGF-e ekspresjonen i hjernen, som Innbefatter administrering til et menneske som har behov for dette av en effektiv mengde av en forbindelse av formel I. Det er videre beskrevet fremgangsmåter for å inhlbere e-amyloidpeptidformidlet neurotokslsitet eller inflammatorisk respons forbundet med Alzheimers sykdom (AD) som Innbefatter administrering til et menneske som har behov for dette av en effektiv mengde av en forbindelse av formel I.
NO944928A 1993-12-21 1994-12-19 Fremgangsmåter for inhibering av Alzheimers sykdom NO944928L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/171,387 US5552415A (en) 1993-12-21 1993-12-21 Method of inhibiting Alzheimer's Disease

Publications (2)

Publication Number Publication Date
NO944928D0 NO944928D0 (no) 1994-12-19
NO944928L true NO944928L (no) 1995-06-22

Family

ID=22623556

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944928A NO944928L (no) 1993-12-21 1994-12-19 Fremgangsmåter for inhibering av Alzheimers sykdom

Country Status (14)

Country Link
US (3) US5552415A (no)
EP (1) EP0659418A1 (no)
JP (1) JPH07215854A (no)
KR (1) KR950016738A (no)
CN (2) CN1087937C (no)
AU (1) AU688815B2 (no)
CA (1) CA2138495A1 (no)
CZ (1) CZ288984B6 (no)
HU (1) HUT71465A (no)
IL (1) IL112050A (no)
NO (1) NO944928L (no)
NZ (1) NZ270177A (no)
RU (1) RU2128992C1 (no)
ZA (1) ZA9410095B (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE4311870C2 (de) * 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US6319914B1 (en) 1993-11-05 2001-11-20 Apollo Biopharmaceuticals, Inc. Cytoprotective effect of polycyclic phenolic compounds
US6197833B1 (en) 1995-07-24 2001-03-06 Apollo Biopharmaceutics, Inc. Neuroprotective effects of polycyclic phenolic compounds
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5859001A (en) * 1996-01-11 1999-01-12 University Of Florida Research Foundation, Inc. Neuroprotective effects of polycyclic phenolic compounds
US6489355B2 (en) * 1993-12-01 2002-12-03 Eli Lilly And Company Methods of inhibiting the effects of amyloidogenic proteins
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
US5434166A (en) * 1994-08-22 1995-07-18 Eli Lilly And Company Methods of inhibiting demyelinating and desmyelinating diseases
US6562862B1 (en) * 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US7069634B1 (en) 1995-04-28 2006-07-04 Medtronic, Inc. Method for manufacturing a catheter
JPH11506923A (ja) * 1995-06-06 1999-06-22 アセナ ニューロサイエンシーズ，インコーポレイテッド 新しいカテプシンならびにその阻害のための方法および組成物
CA2227634A1 (en) * 1995-07-24 1997-02-06 University Of Florida Research Foundation, Inc. Use of non-estrogen polycyclic phenol compounds for the manufacture of a medicament for conferring neuroprotection to cells
IL120269A0 (en) * 1996-02-28 1997-06-10 Pfizer 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's disease
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
US5846220A (en) 1996-04-30 1998-12-08 Medtronic, Inc. Therapeutic method for treatment of Alzheimer's disease
US7189222B2 (en) 1996-04-30 2007-03-13 Medtronic, Inc. Therapeutic method of treatment of alzheimer's disease
US6642261B2 (en) 1997-11-21 2003-11-04 Athena Neurosciences, Inc. N-(aryl/heteroarylacety) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6096782A (en) * 1996-11-22 2000-08-01 Athena Neurosciences, Inc. N-(aryl/heteroaryl) amino acid derivatives pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
EP1015013A4 (en) * 1997-01-10 2002-07-24 Massachusetts Inst Technology TREATMENT OF NEUROTOXICITY IN ALZHEIMER'S DISEASE BY BETA-AMYLOID PEPTIDES
US6942963B1 (en) 1997-01-10 2005-09-13 Massachusetts Institute Of Technology Methods for identifying treatments for neurotoxicity in Alzheimer's disease caused by β-amyloid peptides
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
AU7237198A (en) * 1997-05-21 1998-12-11 Shionogi & Co., Ltd. Remedies for dementia of alzheimer type containing gamma-sultam derivatives
US5990129A (en) * 1997-09-23 1999-11-23 Eli Lilly And Company Methods for regulating trkA expression
US6096781A (en) 1997-11-14 2000-08-01 Eli Lilly And Company 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome
WO1999051587A1 (fr) * 1998-04-01 1999-10-14 Ono Pharmaceutical Co., Ltd. Derives de thiophene condenses et medicaments contenant ceux-ci comme principe actif
KR20010052891A (ko) * 1998-06-16 2001-06-25 피터 지. 스트링거 아세틸콜린 수치를 상승시키는 방법
US6288108B1 (en) 1998-06-16 2001-09-11 Eli Lilly And Company Methods for increasing levels of acetylcholine
IL138914A0 (en) * 1998-06-16 2001-11-25 Lilly Co Eli Methods for increasing levels of acetylcholine
EP0976404A3 (en) * 1998-07-30 2001-06-27 Pfizer Products Inc. A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal
US6087378A (en) * 1998-10-13 2000-07-11 Eli Lilly And Company Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome
ATE301129T1 (de) 1999-05-04 2005-08-15 Strakan Int Ltd Androgen glykoside und die androgenische aktivität davon
US6339078B1 (en) 1999-07-20 2002-01-15 University Of Florida Research Foundation, Inc. Methods of prevention and treatment of ischemic damage
US6326365B1 (en) 1999-07-20 2001-12-04 Apollo Biopharmaceutics, Inc. Methods of prevention and treatment of ischemic damage
AR027878A1 (es) * 1999-11-05 2003-04-16 Wyeth Corp Metodos para identificar y utilizar compuestos inhibidores de amiloides
WO2002035987A2 (en) * 2000-11-03 2002-05-10 Massachusetts Institute Of Technology METHODS FOR IDENTIFYING TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED BY β-AMYLOID PEPTIDES
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
US7067550B2 (en) * 2000-11-03 2006-06-27 Massachusetts Institute Of Technology Treatments for neurotoxicity in Alzheimer's Disease
TWI245764B (en) 2001-04-23 2005-12-21 Hank F Kung Amyloid plaque aggregation inhibitors and diagnostic imaging agents
DE10163239A1 (de) * 2001-12-21 2003-07-10 Aventis Pharma Gmbh Substituierte Imidazolidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie enthaltendes Medikament
PT1511710E (pt) 2002-05-31 2014-02-26 Proteotech Inc Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク Ｘ線回折による応力測定法
WO2005105063A1 (en) * 2004-05-03 2005-11-10 Universita' Degli Studi Di Firenze Pharmaceutical compositions containing serms for the treatment of alzheimer's disease
US20080312587A1 (en) * 2005-06-10 2008-12-18 Gruenethal Gmbh System for the Oral Administration of Solids to Persons Suffering from Dementia
DE102005028862A1 (de) * 2005-06-22 2007-01-11 Sanofi-Aventis Deutschland Gmbh Substituierte Heterocyclen, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
ES2332687B1 (es) * 2008-03-13 2011-01-10 Proyecto De Biomedicina Cima, S.L. Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
WO2010009327A1 (en) 2008-07-17 2010-01-21 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compounds for the treatment of pathologies associated with aging and degenerative disorders
EP2435563A4 (en) * 2009-05-29 2013-10-02 Univ Columbia MODULATION OF PHOSPHOLIPASE D FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM
AU2019211717B2 (en) * 2018-01-24 2024-06-13 Mitsui Sugar Co., Ltd. Anti-I-type allergy agent, degranulation inhibitor for basophils and mast cells, anti-dementia agent, agent for improving/inhibiting short-term memory impairment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7461M (no) * 1968-06-19 1970-01-05
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
WO1993011074A1 (en) * 1991-11-25 1993-06-10 Healthguard, Incorporated Multistage coaxial encapsulated filter assembly
DE4311870C2 (de) * 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
IL109990A (en) * 1993-06-21 1999-06-20 Lilly Co Eli Materials and methods for screening anti-osteoporosis agents
DE4320896A1 (de) * 1993-06-24 1995-01-05 Denecke Rainer Dr Med Vet Präparat zur Therapie und Prophylaxe von Demenz-Erkrankungen
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy

Also Published As

Publication number Publication date
CA2138495A1 (en) 1995-06-22
US5652259A (en) 1997-07-29
US5686476A (en) 1997-11-11
AU688815B2 (en) 1998-03-19
NZ270177A (en) 1997-08-22
CN1294913A (zh) 2001-05-16
AU8154694A (en) 1995-06-29
RU2128992C1 (ru) 1999-04-20
IL112050A (en) 1999-03-12
HUT71465A (en) 1995-11-28
JPH07215854A (ja) 1995-08-15
HU9403668D0 (en) 1995-02-28
CN1108098A (zh) 1995-09-13
CN1087937C (zh) 2002-07-24
ZA9410095B (en) 1996-06-19
IL112050A0 (en) 1995-03-15
US5552415A (en) 1996-09-03
EP0659418A1 (en) 1995-06-28
KR950016738A (ko) 1995-07-20
CZ322094A3 (en) 1995-09-13
NO944928D0 (no) 1994-12-19
CZ288984B6 (cs) 2001-10-17
RU94045155A (ru) 1996-11-10

Similar Documents

Publication Publication Date Title
NO944928L (no) Fremgangsmåter for inhibering av Alzheimers sykdom
NO944911L (no) Ikke-peptid-takykininreseptorantagonister
NO971520L (no) Fremgangsmåte for hemming av tilstander forbundet med neuropeptid Y
NO944914L (no) Fremgangsmåte for å inhibere autoimmunsykdommer
NO944927L (no) Fremgangsmåte for inhibering av pulmonar hypertensiv sykdom
NO973635L (no) Fremgangsmåte for hemming av celle-celle adhesjon
NO944932L (no) Hemming av trombin
UA26930C2 (uk) Засіб для іhгібуваhhя еhдометріозу
NO944919L (no) Fremgangsmåte for å inhibere atrofi av huden eller vagina
ATE147071T1 (de) 1,4-disubstituierte piperidinderivate, ihre herstellung und therapeutische verwendung
DE69430465D1 (de) Hemmung uteriner Fibrose
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
ES2141957T3 (es) Uso de raloxifeno y sus analogos para la produccion de un medicamento para el tratamiento de enfermedades virales.
NO944930D0 (no) Hemming av dysfunksjonell uterin blödning
NO944926L (no) Fremgangsmåter for å inhibere myeloperoksidaseaktivitet
DK0652000T3 (da) Anvendelse af 2-phenyl-3-aroylbenzothiophener til fremstilling af et lægemiddel til inhibering af angiogenese og angiogene sygdomme
NO944933L (no) Fremgangsmåte for å inhibere sykdomstilstander i brystet
NO944915L (no) Öking av trombomodulinekspresjon
NO944924L (no) Fremgangsmåter for inhibering av Turner's syndrom
NO944931L (no) Anvendelse av 2-fenyl-3-aroylbenzotiofener for inhibering av tidlig seksuell modenhet
NO975580L (no) Fremgangsmåte for å inhibere melanom
NO944923L (no) Hemming av vektökning eller indusering av vekttap
NO973367L (no) Fremgangsmåte for å inhibere miljömessige östrogen
NO981578L (no) FremgangsmÕte for hemming av plasminogenaktivatorhemmer I
NO973609L (no) Fremgangsmåte for å inhibere effektene av IL-6